Poor water solubility often leads to low bioavailability due to low dissolution velocity. Isradipine a potent calcium channel blocker exhibits poor water solubility and thus have inadequate bioavailability. The objective of the present work was to develop and characterize solid nanoemulsion preconcentrate of Isradipine. For this a optimized liquid self-nanoemulsifying drug delivery system (SNEDDS) of Isradipine was formulated. The optimized liquid SNEDDS consist of Isradipine, Capmul MCM EP, Tween 80 and Polyethylene glycol 400 in the weight ratio of 1.64:9.82:44.27:44.27, produces SNEDDS with lower particle size 16.31nm, polydispersity index 0.19, and zeta potential -3.10. The optimized liquid SNEDDS formulation was converted into excellent free flowing solid nanoemulsion preconcentrate of Isradipine by adsorbing onto Neusilin UFL2® a solid carrier. The dissolution characteristics of solid nanoemulsion preconcentrate filled into hard gelatin capsules was investigated and compared with liquid SNEDDS formulation and pure drug to ascertain the impact on dissolution following conversion. The results indicated that solid nanoemulsion preconcentrate showed comparable rate and extent of drug dissolution in a dissolution medium as liquid SNEDDS but have higher dissolution than the pure drug. Thus, Solid Nanoemulsion Preconcentrate combines the advantages of liquid SNEDDS (i.e. enhanced solubility) with those of solid dosage form (e.g. low production cost, convenience of process control, high stability and reproducibility, better patient compliance). The results from this study demonstrates that solid nanoemulsion preconcentrate may be use as a means of improving solubility, dissolution, and ultimately the bioavailability of Isradipine.
Loading....